Understanding the regulatory networks that hnk signals at the cell surface to transcriptional responses in the nucleus represents a major challenge of molecular biology. Elucidation of the molecular details of these intracellular pathways requires the identification of specific signaling molecules that act at the cell membrane to initiate a cellular response and the characterization of cisacting DNA sequences and trans-acting factors that serve as nuclear targets for these pathways. Skeletal myoblasts offer an attractive model for studying the mechanisms whereby extracellular signals modulate gene expression because a defined set of polypeptide growth factors has been identified that can block the induction of a battery of genetically unlinked muscle-specific genes (for review, see Florini et al. 1991) .
One approach taken to identify intracellular signaling pathways through which growth factors inhibit myogenesis has involved transfection of myoblasts with activated oncogenes whose products are known to transduce ^Corresponding author. growth signals from the cell membrane to the nucleus. These studies have revealed that members of the ras family Lassar et al. 1989a) , as well as certain membrane-associated tyrosine protein kinases (Falcone et al. 1985) , can mimic the inhibitory actions of growth factors on the differentiation program. Similarly, forced expression of Fos or Jun, which together comprise the AP-1 complex that confers growth factor responsiveness to several genes (Angel et al. 1987; Bohmann et al. 1987; Chiu et al. 1988) , can disrupt myogenesis (Ball et al. 1988; Lassar et al. 1989a; Bengal et al. 1992) . Deregulated expression of c-and w-myc also can inhibit muscle-specific gene expression (Falcone et al. 1985; Schneider et al. 1987; Miner and Wold 1991) . Many of these oncogene products function in pathways regulated by protein kinase C, which itself can inhibit myogenesis when activated by tumor-promoting phorbol esters (Lin et al. 1987) .
Recent studies have revealed a family of muscle-specific nuclear factors that can activate the complete array of skeletal muscle genes when expressed artificially in fibroblasts (for reviews, see Olson 1990; Weintraub et al. 1991 ). This family of proteins, which includes MyoDl (Davis et al. 1987) , myogenin (Edmondson and Olson 1989; Wright et al. 1989) , myf-5 (Braun et al. 1989) , and MRF-4 , shares extensive similarity within a myc homology domain that contains a basic region and a putative helix-loop-helix (HLH) motif, which have been implicated in DNA binding and dimerization (Murre et al. 1989; Davis et al. 1990; Brennan et al. 1991a ). Upon heterodimerization with E2A gene products £12 and E47, the myogenic regulatory factors acquire high affinity for the DNA sequence CANNTG, referred to as an E box, which is present in the control regions of numerous muscle-specific genes (Murre et al. 1989; Brennan and Olson 1990; Davis et al. 1990; Chakraborty et al. 1991) . The muscle creatine kinase (MCK) gene has been shown to be regulated primarily by a distal upstream enhancer that contains two E boxes that direct muscle-specific transcription through interaction with myogenic HLH proteins (Lassar et al. 1989b; Brennan and Olson 1990 ).
There is an intriguing antagonism between the actions of myogenic HLH proteins and signals generated by growth factors. Expression of MyoD at high levels, for example, can suppress cell proliferation and activate muscle-specific genes, even in the presence of growth factors or activated oncogenes that would normally inhibit myogenesis (Davis et al. 1987; Crescenzi et al. 1990; Sorrentino et al. 1990 ). Conversely, high concentrations of fibroblast growth factor (FGF), transforming growth factor-p (TGF-p), or fetal bovine serum can override the actions of MyoD and myogenin and repress the ability of these proteins to activate muscle-specific genes (Davis et al. 1987; Vaidya et al. 1989; Brennan et al. 1991b and references therein). Negative regulation of MyoD function is also apparent during myogenesis, when the MyoD protein is expressed constitutively in proliferating myoblasts prior to initiation of differentiation, and becomes "activated" upon withdrawal of exogenous growth factors (Davis et al. 1987) . These observations suggest that there is a convergence of growth factor-signaling pathways and pathways controlled by members of the MyoD family and that the decision of a myoblast to differentiate or divide is dictated by a balance between these antagonistic programs. Little is known, however, of the mechanisms whereby growth factor and oncogenic pathways suppress the activities of myogenic HLH proteins.
The availability of cloned regulatory factors that can directly activate muscle-specific genes through interaction with defined DNA sequences offers an opportunity to dissect the mechanisms whereby growth factor and oncogenic signals block muscle-specific transcription. In this study we used the 5'-flanking region of the MCK gene as a target to investigate whether members of the Fos and Jun families of growth factor-inducible early genes can substitute for exogenous growth factors and block the actions of myogenin and MyoD. We show that Fos and Jun can specifically repress transcriptional activation by myogenic HLH proteins and that the amino terminus of c-Jun is important for efficient repression.
Our findings demonstrate that there is cross talk between myogenic HLH proteins and transcription factors that positively regulate cell growth and provide evidence for a pathway through which members of the Fos and Jun families can repress muscle-specific gene expression.
Results

Fos blocks myogenin-and MyoD-dependent activation of MCK control sequences
To analyze for possible regulatory interactions between myogenin and various growth factor-inducible early gene products, we used muscle-specific regulatory sequences from mck linked to a chloramphenicol acetyltransferase (CAT) reporter gene. Induction of mck is dependent on a muscle-specific enhancer that lies between -1350 and -1048 relative to the transcription initiation site (Jaynes et al. 1988; Sternberg et al. 1988) . This enhancer contains a high-affinity binding site for myogenin and MyoD that is essential for muscle specificity and trans-activation by these myogenic regulatory factors Lassar et al. 1989b; Brennan and Olson 1990) . The chimeric reporter gene MCK-CAT, which contains the 246-bp MCK promoter fused immediately upstream of CAT and the 302-bp enhancer inserted 3' of CAT, is strictly muscle specific (Sternberg et al. 1988 ) and was used in initial experiments. pendent on the MCK enhancer and is not observed with the MCK promoter alone, under the conditions of these assays (Edmondson and Olson 1989) . When transfection assays were performed in the presence of the c-Fos expression vector, trans-activation of MCK-CAT by myogenin was suppressed. This suppression was not observed using a frameshift mutant of c-Fos (A-Fos) that is biologically inactive (Fig. lA) . The lack of repression by the A-fos plasmid shows that the c-Fos expression vehicle does not repress MCK-CAT by competing for limiting transcription factors. v-Fos, encoded by the vector FBJ-/OS (van Beveren et al. 1983) , was also able to block £rfl22s-activation of MCK-CAT by myogenin; the extent of suppression was dependent on the relative ratios of myogenin and v-Fos expression vectors (Fig. IB) . Suppression of MCK-CAT by v-and c-Fos also did not reflect a generalized effect on transcription, as Rous sarcoma virus (RSV)-CAT, which contains the constitutively active RSV promoter and enhancer, was not suppressed by cotransfection with the Fos expression vectors (data not shown). In addition, the reporter -73Col-CAT, which contains the AP-1 responsive collagenase promoter (Angel et al. 1987) , is activated by c-Fos (data not shown). To rule out the possibility that v-Fos and c-Fos indirectly prevented activation of MCK-CAT by inhibiting myogenin expression from the Maloney sarcoma virus long terminal repeat (MSV-LTR) in the EMSV-myogenin expression vector, we measured myogenin mRNA expression in transiently transfected cells by Northern analysis and found it to be unaffected in the presence of cotransfected plasmids (data not shown).
Myogenic HLH proteins can discriminate between different members of the fun family
We also investigated whether members of the jun family of oncogenes influenced the actions of myogenin. Figure  2 shows that trans-activation of MCK-CAT by myogenin was suppressed by cotransfection of an expression vector encoding JunB, c-Jun, and v-Jun, whereas a frameshift mutant in the c-Jun open reading frame that does not encode a functional protein (c-Jun™"') was without effect. As with the Fos expression vectors, the Jun expression vectors did not inhibit expression of RSV-CAT or expression of myogenin driven by the MSV-LTR (data not shown).
In contrast to the junB and c-jun genes, which are expressed at a basal level in differentiated myocytes and are rapidly up-regulated by growth factors that inhibit myogenesis, the junD gene is expressed at high levels in muscle cells, as well as other types, and is not regulated during differentiation (Ryder et al. 1989; Li et al. 1990 ). We therefore examined the specificity of trans-repression using an expression vector encoding JunD. As shown in Figure 2 , JunD failed to block activation of MCK-CAT by myogenin. At the plasmid ratios used in these experiments, we observed reproducibly a stimulation of MCK-CAT of ~ 1.5-to 2-fold by JunD. Because all of the Jun cDNAs were contained in the same expression vector and radioimmunoprecipitation indicates that they led to synthesis of similar amounts of protein in F9 cells (T. Smeal, unpubl.) , these results suggest that the actions of JunB and c-Jun are distinct from those of JunD. To determine whether sensitivity to repression by Fos and Jun was a general property of myogenic HLH proteins, we examined whether Fos and Jun proteins were able to repress activation of MCK-CAT by MyoD. As reported previously (Lassar et al. 1989a ), c-Fos was a potent repressor of MyoD activity (Fig. 3A) . v-Jun was also an efficient repressor of MyoD, whereas c-Jun was relatively less effective. Nearly complete inhibition by c-Jun was achieved, however, when higher amounts of the expression vector were used (data not shown). The combination of c-Jun -I-c-Fos resulted in repression to a level similar to that observed with c-Fos alone (Fig. 3A) . We also investigated whether increasing the level of MyoD could overcome inhibition by Fos and Jun. As shown in Figure 3B , increasing the amount of cotransfected MyoD could partially overcome the inhibition by c-Fos and v-Jun. These results suggest that muscle-specific gene activation is determined by the ratio of MyoD or myogenin to Fos or Jun. 
Trans-activation by E2-5 is unaffected by c-Fos and v-fun
Activation of muscle-specific transcription by myogenin and MyoD requires hetero-oligomerization v^ith E2A products, such as E12 and E47 (Lassar et al. 1991) . Repression of the activity of myogenin and MyoD by Fos and Jun could formally be mediated indirectly by inhibiting the activity of E2A products. To investigate whether Fos and Jun affected the activity of E2A products, we tested the ability of E47, also called E2-5, to trans-activate a reporter gene linked to a multimerized E box that serves as the target sequence for E47. The reporter gene used for these experiments, (£2 + 8)4-TATA-CAT, contains four copies of the |xE2 and |xE5 E boxes upstream of a basal promoter and is strongly transactivated by E47 (Henthom et al. 1990 ). As shown in Figure 4 , this target gene showed low activity in lOTl/2 cells, presumably owing to low-level expression of endogenous E2A products. However, when cotransfected with an E47 (E2-5) expression vector, high levels of expression of the reporter gene were observed. Neither v-Fos nor c-Jun significantly diminished the level of trans-activation of the reporter gene by E2-5. The v-Fos and c-Jun expression vectors also had no effect on expression of the reporter gene in the absence of E2-5 (data not shown). It is conceivable that higher concentrations of Fos or Jun might repress trans-activation by E2-5, but the apparent lack of sensitivity of E2-5 to repression at concentrations of the Fos and Jun expression vectors that extinguish activation by myogenin and MyoD argues against a role for E2-5 as a target for repression. These results suggest, therefore, that repression by Fos and Jun is targeted specifically at myogenic HLH proteins. 
The MCK enhancer is repressed by Fos and Jun through the E box in the enhancer core
Suppression of MCK-CAT by Fos and Jun could, in principle, be mediated by the MCK promoter or the enhancer. To determine whether the enhancer was the target for trans-repression, we used a reporter gene, pSVCATCKe, in which the 302-bp MCK enhancer (-1350/-1048) was combined with the SV40 promoter, which is active in lOTl/2 cells. Figure 5A shows that this reporter gene could be trans-activated by myogenin and that trans-activation was suppressed by v-Fos, JunB, or v-Jun. The ability of myogenin to trans-activate this reporter plasmid agrees with previous studies in which the MCK enhancer was defined as a target for myogenindependent activation (Edmondson and Olson 1989) . To exclude the possibility that repression of pSVCATCKe might be mediated by the SV40 promoter, pSV2CAT, which contains the SV40 promoter and enhancer, was used in transfection assays. Consistent with previous observations (Edmondson and Olson 1989) , myogenin trans-activated this reporter weakly. This is probably the result of the presence of two E box sequences within the SV40 promoter (Tooze 1981) . Trans-activation of pSV2CAT by myogenin was reduced in the presence of v-Fos and JunB, but the basal activity of the reporter was not suppressed, indicating that v-Fos and JunB did not repress the SV40 promoter. v-Fos, v-Jun, and JunB also did not repress activity of pSV2CAT in the absence of myogenin (Angel et al. 1988 , and data not shown).
Fos and Jun regulate transcription of a variety of genes through interaction with a DNA sequence known as an AP-1 site, TGAG/CTCA (Angel et al. 1987 (Angel et al. , 1988b Bohmann et al. 1987; Lee et al. 1987; Piette and Yaniv 1987; Chiu et al. 1988 ). There are no AP-1 sites within the MCK enhancer that could serve as potential targets for binding of Fos/Jun. Gel mobility-shift assays performed with DNA fragments encompassing the MCK enhancer and in vitro translation products of c-Fos, c-Jun, and JunB, alone and in combination, also failed to reveal measurable interactions (data not shown). Repression of the c-/os promoter by c-Fos and c-Jun was shown to be mediated by the serum response element (Konig et al. 1989) , which is closely related to the CArG motif, CC(A/T)6GG (Minty and Kedes 1986) . CArG motifs are present in the control regions of numerous muscle-specific genes and are important for muscle-specific transcription (Minty and Kedes 1986) ; a CArG motif is present at -1234/-1224 in the MCK enhancer (Sternberg et al. 1988) . To assess the role of this site in mediating trans-repression, we created a mutation at that site and left the remainder of the 302-bp enhancer intact (mutant CArG; Fig. 5B ). In addition, we tested a deletion mutant containing the 3' half of the enhancer (-1204/ -1048, mutant e6; Fig. 5B ), which lacks the CArG motif, for responsiveness to v-Fos, JunB, or v-Jun. Both enhancer mutants were activated by myogenin and repressed by v-Fos and JunB, indicating that the CArG motif does not mediate trans-repression and the elements involved in activation and repression map to the region between -1204 and -1048. It is noteworthy that deletion mutant e6 also removes a perfect AP-2 site (-1216/-1209), which has been shown to mediate the actions of growth factor signals on a variety of genes .
Activation of the MCK enhancer involves cooperative interactions among myogenic HLH proteins that bind to an E box referred to as the MEF-1 site and other enhancer-binding factors that bind to surrounding sites (Gossett et al. 1989 ; P. Cserjesi, B. Lilly, and E. Olson, unpubl.) . To determine whether trans-repression is mediated through the MEF-1 site, we tested whether v-Fos, JunB, and v-Jun block trans-activation of the (MEF-1 )4-tkCAT reporter, which contains four MEF-1 sites upstream to the thymidine kinase basal promoter. Trans-activation of the thymidine kinase promoter in this reporter plasmid by MyoD requires a minimum of two MEF-1 sites ). As shown in Figure 5C , myogenin strongly trans-activated this reporter in lOTl/2 cells, and v-Fos, JunB, and v-Jun inhibited trans-activation. Repression of (MEF-1 )4-tkCAT by Fos and Jun was dependent on the MEF-1 sites, and myogenin and was not observed with tkCAT lacking these sites. Repression is therefore targeted at the MEF-1 sites and is not mediated indirectly by the thymidine kinase promoter ( Fig. 5C ; see also Angel et al. 1988a; Yang-Yen et al. 1990 ).
The amino terminus c-fun mediates repression
To determine which regions of c-Jun are important for inhibition of myogenin and MyoD activity, we examined the ability of several deletion derivatives of c-Jun to repress trans-activation of MCK-CAT. As shown in Figure  6A , deletion of amino acids 1-87 or 6-223 from c-Jun resulted in a large decrease in its ability to repress myogenic activity. These regions of c-Jun encompass the transcriptional activation domains . Previous transfection experiments indicate that c-JunAl-87, and c-JunA6-223 are stable nuclear proteins that accumulate in amounts similar to the wild-type c-Jun protein ). Dimerization does not appear to be essential for repression because a c-Jun mutant that lacks the leucine zipper (c-JunALZ) (Schule et al. 1990 ) also showed inhibitory activity. The leucine zipper does appear to contribute to repression, however, because c-JunALZ was a less potent inhibitor than wild-type c-Jun. Because there is a delicate balance between the amount of myogenic regulator and c-Jun needed for repression, and we have only measured potential repression of myogenin and MyoD by c-Jun mutants at a single ratio of expression vectors, we cannot rule out the possibility that mutants with diminished inhibitory activity might fully repress muscle transcription at higher concentrations.
To further investigate the repression mediated by the amino terminus of c-Jun, we examined whether a chimeric protein containing the amino-terminal half of c-Jun fused to the DNA-binding domain of GHFl, a pi- Relative irans-activailpn tuitary-specific transcription factor with a different DNA-binding site from Fos/Jun (Bodner et al. 1988) , could repress activation by myogenin and MyoD. This chimera (c-Jun-GHFl) was an extremely efficient repressor of t/fl/25-activation by the myogenic regulators (Fig.  6A) . Little or no inhibition was observed with GHFl alone. We reproducibly observed that c-Jun-GHFl was more potent than wild-type c-Jun in its ability to repress myogenin and MyoD. We believe the enhanced inhibitory activity of this chimera is the result of its longer half-Hfe compared with that of c-Jun (B. Binetruy and T. Smeal, unpubl.). When equal amounts of c-Jun and c-Jun-GHFl expression vectors were transfected into F9 cells, which lack endogenous c-Jun (Chiu et al. 1989 ; Yang-Yen et al. 1990a), the level of c-Jun-GHFl protein was ~ 10-fold higher than that of c-Jun protein, as tested by Western blot using antibody against the amino terminus of c-Jun (Fig. 6B) .
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To further investigate the ability of c-Jun-GHFl to repress muscle-specific gene activation, we introduced the c-Jun-GHFl expression vector with a hygromycinresistance gene stably into the myogenic cell line 10TFL2-3, which expresses myogenin constitutively (Brennan et al. 1991b) . Whereas greater than half of the clones obtained with the hygromycin-resistance gene alone were able to terminally differentiate, there was almost no detectable differentiation of clones transfected with the c-Jun-GHFl expression vector (Table 1) . The amino terminus of c-Jun can therefore inhibit the transcription-activating functions of myogenin in transiently or stably transfected cells, indicating that c-JunGHFl does not affect cell viability and that repression does not result simply from overexpression that may occur in transient assays.
Repression by Fos and fun is directed at the basic-HLH motif
The basic-HLH (bHLH) regions of myogenin and MyoD are required for DNA binding and collaborate with activation domains in the amino and carboxyl termini of these proteins to activate muscle-specific transcription (Brennan et al. 1991a; Weintraub et al. 1991; Schwarz et al, 1992) . To determine whether trans-activation and sensitivity to trans-repression were mediated by separable domains, several deletion mutants of myogenin were tested for their responsiveness to Fos and Jun. As shown in Figure 7A , either the amino or carboxyl termini of myogenin could be deleted, with a partial loss in myogenic activity (mutants AN-myo and AC-myo, respectively); deletion of the carboxyl terminus had a more dramatic effect on activity. The activity of both constructs was inhibited by Fos and Jun. However, if both the amino and carboxyl termini were deleted, leaving The cell line 10TFL2-3 was stably transfected with a hygromycin-resistance gene alone (control) or with c-}un-GHFl as described in Materials and methods. Fourteen days after selection for hygromycin-resistance, plates were transferred to DM for 6 days. Colonies were then counted and the number containing multinucleate myotubes was determined.
just the bHLH region, all measurable myogenic activity was lost (ANAC-myo). Expression of the proteins encoded by each myogenin deletion mutant in transfected cells has been demonstrated (Schwarz et al. 1992 ). These results suggest that neither the amino-nor the carboxyterminal activation domains of myogenin are essential for sensitivity to trans-repression. Because the bHLH region alone (ANAC-myo) was inactive in the trans-activation assay, we could not assay the effects of Fos and Jun on that domain directly. We therefore used a chimera in which the acidic activation domain of the acidic coactivator VP16 was fused to the carboxyl terminus of the bHLH deletion mutant to test the responsiveness of this region to trans-repression. This chimera, called ANAC-VP16, was highly active against the (MEF-l)4-tkCAT reporter and was repressed by v-Fos and c-|un-GHFl (Fig.  7B) . The repression of ANAC-myo-VP16 by v-Fos and c-Jun-GHFl was not the result of the squelching of the VP16 activation domain because a Gal4-VP16 chimera was insensitive to repression under this condition. Collectively, these results suggest that Jun and Fos interfere with the activity of the bHLH region of myogenin.
Discussion
Serum and peptide growth factors, such as FGF and TGF-P, have been shown previously to suppress the activation of muscle-specific genes (for review, see Florini et al. 1991) . Here, we show that (1) v-Fos, c-Fos, v-Jun, c-Jun, and JunB can mimic the inhibitory effects of growth factors on myogenesis and silence the transcriptional activating capacity of the muscle-specific activators myogenin and MyoD; (2) the high-affinity E box within the MCK enhancer core is a target for trans-repression by Fos and Jun proteins; (3) amino-terminal sequences of c-Jun are sufficient for efficient inhibition of myogenin and MyoD activity; (4) the bHLH domain of myogenin appears to be the target for the repressive effects of Fos and Jun; (5) repression by Fos and Jun is a specific property of myogenic HLH proteins and is not observed with other bHLH proteins such as E47.
What types of mechanisms might account for the ability of Fos and Jun to block the actions of myogenin and MyoD? The amino terminus of c-Jun, which has the potential to repress myogenin and MyoD function, has been shown to contain a transcription activation domain . The requirement for an intact amino terminus for efficient repression of myogenin and MyoD activity by c-Jun is consistent with the notion that inhibition reflects competition for a limiting amount of a common target required for activation, a phenomenon known as squelching (Ptashne 1988 ). However, squelching through competition for a general transcription factor seems unlikely because neither Jun nor Fos interferes with expression of most other genes and transformation by Jun and Fos does not affect cell viability (Ball et al. 1988; Lassar et. al. 1989a; L. Li and E. Olson, unpubl.) . That repression by Jun and Fos is not a general transcriptional response was demonstrated by their failure to inhibit trans-activation by E47, the lack of repression of the SV40 and thymidine kinase promoters, and the lack of inhibition of VP16. Thus, these findings support the idea that transcriptional interference by c-Jun is specific to the myogenic factors.
Although c-and v-Fos also repress the activity of myogenin and MyoD, repression by Fos may not occur through the same mechanism as for Jun. The lack of sequence similarity between Fos and Jun outside the DNA-binding and dimerization domain suggests that Fos may repress through a different mechanism than Jun. The absence of cooperativity between Fos and Jun in repression also suggests that repression by Fos does not involve the formation of a functional AP-1 complex.
Although our results suggest that the amino-terminal region of c-Jun may repress myogenin and MyoD activity through a mechanism involving competition for a limiting factor, they do not rule out the possibility that these early gene products could interact directly with myogenic HLH proteins to inhibit their activities in a manner analogous to the mechanism through which they repress glucocorticoid receptor (GCR) function (Diamond et al. 1990; Jonat et al. 1990; Schule et al. 1990; Yang-Yen et al. 1990b) . In this regard, the bHLH of MyoD has recently been shown to interact directly with the leucine zipper of c-Jun (Bengal et al. 1992) . Consistent with this mechanism for repression, we observed that deletion of the basic region and leucine zipper diminished the inhibitory activity of c-Jun. However, the observation that the leucine zipper-deficient protein c-JunALZ, which is incapable of repressing GCR function (Schule et al. 1990; Yang-Yen et al. 1990b) , retains inhibitory activity, and that the c-Jun-GHFl chimera can repress myogenin and MyoD, argues for two different mechanisms of transcriptional interference by c-Jun. c-Jun and JunB both repress the activity of myogenin and MyoD but differ in their activities against AP-1-containing target genes. JunB inhibits transcriptional activation by c-Jun (Chiu et al. 1989 ). We have not yet mapped the sequences in JunB responsible for repression of muscle transcription. However, mapping of the sequences that account for the different abilities of c-Jun and JunB to activate AP-1 target genes indicates that the critical sequences reside within the basic region and leucine zipper. The amino-terminal activation domains of c-Jun and JunB have very similar transcriptional activities (T. Deng and M. Karin, in prep.) . In contrast to c-Jun and JunB, which repressed musclespecific transcription and are induced by growth factors that inhibit myogenesis (Li et al. 1990) , JunD had no effect on trans-activation by myogenin. The failure of JunD to affect muscle-specific transcription is consistent with the observation that JunD is expressed constitutively in myoblasts and is not regulated during myoblast proliferation or differentiation (Li et al. 1990 ). The inability of JunD to repress transcriptional activation by myogenin also supports the conclusion that the leucine
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c-Jun and JunD contain segments with high homology and regions of divergence within their amino termini. The failure of JunD to repress myogenin efficiently suggests that its divergence in the amino terminus precludes repression, perhaps by mediating protein-protein interactions distinct from those of c-Jun. JunD is also incapable of activating an AP-1-dependent reporter (Yang-Yen et al. 1990a) . JunD also fails to inhibit estrogen receptor activity, whereas c-Jun and JunB are potent repressors of the estrogen receptor. Repression of estrogen receptor activity by c-Jun has been mapped to a region within the amino terminus (Doucas et al. 1991) . Overexpression of JunD also has no effect on cell growth, whereas c-Jun, and to a lesser extent JunB, can induce cellular transformation (Castellazzi et al. 1991) . Analysis of c-Jun deletion mutants has shown that the aminoterminal portion (amino acids 2-168) is required for transformation (Alani et al. 1991) and that the DNAbinding and dimerization sequences of c-Jun can be replaced with those of JunD without a loss in transforming activity (Castellazzi et al. 1991) . Therefore, in different biological events, members of the Jun family can function differently. For instance, JunB demonstrates effects on myogenin similar to that of c-Jun, even though JunB has been shown to be a negative regulator of c-Jun (Chiu et al. 1989 ).
The observation that repression by Fos and Jun is targeted at the bHLH region, which itself lacks the potential to activate transcription (Schwarz et al. 1992) , suggests that these proteins may compete for interaction with a third factor that normally interacts with the bHLH region to activate muscle-specific transcription. Such a factor would presumably be specific for the myogenic bHLH because transcriptional activation by E47 was insensitive to repression by Fos and Jun. In this regard, the basic regions of myogenin and MyoD contain a conserved recognition sequence that has been proposed to interact with a coregulator to induce muscle transcription Brennan et al. 1991; Weintraub et al. 1991b) . Mutagenesis studies suggest that such a coregulator would not recognize the basic regions of E2A proteins and would not be essential for transcriptional activation by this class of bHLH proteins. Experiments are under way to determine whether the amino terminus of c-Jun interacts with proteins from myotube nuclear extracts that may fulfill the criteria of such a coregulator.
It is conceivable that Fos or Jun could induce the expression of an inhibitory factor that suppresses musclespecific transcription, but this type of mechanism seems less likely to explain repression by c-Jun because replacement of the DNA-binding domain of c-Jun with the corresponding domain of GHFl, a pituitary-specific transcription factor with an entirely different sequence specificity (Bodner et al. 1988) , does not impair its ability to inhibit myogenin and MyoD activity. The c-Jun-GHFl chimera is unlikely to activate the same set of target genes as Jun and Fos. Because this chimera is unable to induce transformation (Alani et al. 1991) , we can also conclude that repression of myogenin and MyoD function is not an indirect consequence of deregulated growth control associated with transformation.
The HLH protein Id, which is expressed at high levels in proliferating cells maintained in mitogen-rich medium and is down-regulated during myogenesis, has been proposed as a potential mediator of the effects of growth signals on myogenesis. Id lacks a basic region and can inhibit DNA binding of other HLH proteins such as El2, E47, and MyoD (Benezra et al. 1990 ). Because Id dimerizes preferentially with E2A products, Fos and Jun would be expected to repress traiis-activation by E47 if they acted through an Id-mediated mechanism. However, our results show clearly that transcriptional repression by Fos and Jun is specific for myogenic HLH proteins and is not observed with E47. Further evidence against a role for Id in repression by v-Fos has recently been obtained through analysis of v-Fos-transformed myoblasts, which down-regulate Id normally upon withdrawal of serum (L. Li and E. Olson, unpubl.) .
What is the biological significance of the transcriptional repression mediated by the amino terminus of c-Jun? Although these studies have primarily involved transient transfection assays, the finding that expression of c-Jun-GHFl together with myogenin in stably transfected cells is sufficient to block activation of musclespecific genes shows that repression by c-Jun can occur at physiological levels of expression and is not restricted to transient transfection assays in which proteins may be expressed at abnormally high levels. A variety of growthrelated signaling pathways initiated at the cell membrane lead to the induction of c-Fos, c-Jun, and JunB (Karin 1990) . It is possible that these gene products accumulate in nuclei in response to growth factor signals and thereby inhibit myogenic differentiation. The possibility that growth factor-inducible early gene products, such as Fos and Jun, might mediate the inhibitory actions of growth factors on the muscle differentiation program was initially suggested by the observation that protein synthesis is required for serum and FGF to repress muscle-specific gene expression (Spizz et al. 1986 ). Signal transduction pathways that involve H-Ras (Imler et al. 1988; Binetruy et al. 1991) , protein kinase C (Angel et al. 1987 (Angel et al. , 1988b Lee et al. 1987; Boyle et al. 1991) , and cAMP-dependent protein kinase (Chiu et al. 1989) , each of which have been implicated in negative regulation of myogenesis (Lin et al. 1987; Olson et al. 1987; Hu and Olson 1988; Lassar et al. 1989a; Vaidya et al. 1991) , lead to induction and activation of Fos and Jun proteins. Thus, it is conceivable that Fos and Jun could act as final mediators for diverse signals that inhibit myogenesis.
Finally, it is intriguing that the decision of a myoblast to proliferate or differentiate seems to be determined by a balance between growth factor-generated signals and differentiation signals mediated by myogenic HLH proteins. Our results and those of others (Lassar et al. 1989a; Bengal et al. 1992 ) support the notion that repression of myogenin or MyoD function by Fos and Jun is a titratable phenomenon that depends on the ratio of these proteins. Considering that the bHLH region is required for growth inhibition by MyoD (Crescenzi et al. 1990; Sorrentino et al. 1990 ) and for sensitivity of myogenin to inhibition by Fos and lun, it is tempting to speculate that antagonism between growth and differentiation in this system may reflect convergence of these regulatory pathways at a common point possibly involving a third factor that interacts with the myogenic bHLH.
Materials and methods
Cell culture and tiansfections
C3H10T1/2 cells were cultured in Dulbecco's modified Eagle medium (DMEM) with 20% fetal bovine serum (FBS) as described previously (Edmondson and Olson 1989) . To initiate differentiation, growth medium (GM) was replaced with DMEM containing 2% horse serum (differentiation medium, DM). For transfections, cells were plated on 10-cm dishes at a density of 5 X 10'' cells per dish in GM. Twenty-four hours later, cultures were refed with 4 ml of GM for 2 hr before transfection. Calcium phosphate precipitates were prepared as described previously (Sternberg et al. 1988 ). Forty-eight hours after transfection, cells were harvested and CAT activity was determined in aliquots of cell extracts containing equivalent quantities of protein. To account for possible nonspecific effects of variable amounts of DNA in the transfection assays, the amount of DNA in all transfections was made equivalent by addition of pUC19 or expression vector lacking a cDNA insert. The 10TFL2-3 cell line was derived from lOTl/2 cells by stable transfection of EMSV-myogenin and a neomycin-resistance gene (Brennan et al. 1991b ). These cells were stably transfected with 50 ng of a hygromycin-resistance gene alone or with 2 ^.g of the c-Jun-GHFl expression vector, and hygromycin-resistant clones were selected as described previously (Sternberg et al. 1988) .
The MCK-CAT reporter genes used for transfections have been described previously (Sternberg et al. 1988) . Briefly, MCK-CAT, referred to previously as pCKCATe4-l-, contains the region -1350/-1048 upstream of mck inserted into the BamWl site 3' of pCK246CAT, which contains the 246-bp mck promoter immediately upstream of CAT. pCKCATe6-(-contains the region -1204/-1048 of mck inserted in the BamHl site of pCK246CAT. pCKCATmutCArG is a derivative of pCKCATe4-l-in which the CArG motif was mutated from CCATGTAAGGAG to CAGATCTGTGGA. pSVCATMCKe contains the SV40 promoter and the mck enhancer, whereas pCKCATSVe contains the m^ck promoter and the SV40 enhancer. (MEF-l)4-tkCAT, also known as 4R-tkCAT, contains four copies of the MEF-1 site from the MCK enhancer immediately upstream of the thymidine kinase basal promoter linked to CAT .
Reporter plasmids were cotransfected with the expression vector pEMSVscribe (EMSV) (Davis et al. 1987) , which contains the MSV-LTR, with or without a myogenin or MyoD cDNA insert, as specified. The following expression vectors were tested for their effects on the trans-activating capacity of myogenin. FBJ-2 contains the v-/os-coding sequence under transcriptional control of the viral LTR (van Beveren et al. 1983) . c-/oscoding sequences were under control of the SV40 promoter and enhancer. A-Fos is a derivative of c-/os that contains a frameshift mutation in the open reading frame (Schonthal et al. 1988). c-jun, c-7'un(mut) , iunB (Ryder et al. 1988b) , and iunD (Li et al. 1990 ) cDNAs were linked to the RSV-LTR (Angel et al. 1988) . The deletion mutants of c-Jun and the chimeras with GHFl are described in Angel et al. (1989) . These mutants are expressed under the control of the RSV-LTR. c-JunALZ (Schule et al. 1990) , also under control of the RSV-LTR, was kindly provided by I. Verma.
The expression plasmid for expression of E2-5 (E47) was pSVE2-5, described previously (Henthorn et al. 1990 ). The reporter plasmid (E2-l-5)4-TATA-CAT contains four copies each of the ^,E2 and |JLE5 sites linked to the alkaline phosphatase TATA box (Henthorn et al. 1990 ).
The activator GAL-VP16 contains the VP16-activating region fused in-frame to amino acids 1-147 of GAL4 in the plasmid pSG424, which contains the SV40 promoter and enhancer (Lillie et al. 1989 ). The GAL4 reporter plasmid was pG5ElbCAT and contains five copies of the GAL4-responsive element (Lillie et al. 1989 ).
Generation of mutants
Mutagenesis of the mck enhancer and myogenin was performed on single-stranded templates as described previously (Brennan et al. 1991a ). All mutations were confirmed by sequencing, and the mutagenic regions were subcloned into wild-type vectors to avoid extraneous mutations outside the mutagenic region. Myogenin deletion mutants and VP16 chimeras have been described elsewhere (Schwarz et al. 1992) . Briefly, AN-myo was created by introducing an in-frame deletion of amino acids 4-79. AC-myo was created by introduction of a stop codon at amino acid 138. ANAC-myo is a combination of AN-myo and AC-myo and contains residues 1-3 fused in-frame to residues 80-137. ANAC-myo-VP16 was created by ligation of a SallBamWl fragment of VP16, which contains the activating region, to the Ncol site (codon 156) of AN-myo. All deletion mutants were confirmed by DNA sequencing.
Western blot analysis
For analysis of expression of c-Jun and c-Jun-GHFl, F9 cells were transiently transfected with the corresponding expression vectors, nuclear extracts were prepared 24 hr later, and c-Jun protein was detected by Western blot using an antibody directed specifically against the amino terminus of c-Jun . The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.
